Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 13/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.73 |
| ▸ | INCENP | Q9NQS7 | 10/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16292275 | 1.00 | TTK (0.73) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL16292500 | 0.97 | TTK (0.74) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL16292499 | 0.97 | TTK (0.74) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL16292181 | 0.92 | TTK (0.77) | TTKCYP3A4AURKBINCENPFLT3 | |
| SCHEMBL14873316 | 0.90 | TTK (0.81) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL16293120 | 0.90 | TTK (0.81) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL16292401 | 0.89 | TTK (0.79) | TTKCYP3A4AURKBINCENP | |
| SCHEMBL16292402 | 0.89 | TTK (0.79) | TTKCYP3A4AURKBINCENP | |
| SCHEMBL16308724 | 0.87 | TTK (0.61) | TTKCYP3A4AURKBINCENPFGFR1 | |
| SCHEMBL18559382 | 0.87 | TTK (0.61) | TTKCYP3A4AURKBINCENPFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | TTK 7/4885CYP3A4 1012/4885AURKB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.